* Note to editors:duloxetine be marketed included for episodes of major depression by Lilly and Boehringer Ingelheim in all countries of the partnership under the brand name Cymbalta, except for Greece, Italy and Spain. In Greece, Italy and Spain Lilly is the product as Cymbalta and Boehringer Ingelheim will market the product as Xeristar. In the USA , the collaboration excludes neuroscience indications.
If the European Commission accepts the recommendation, the approval of duloxetine for diabetic peripheral neuropathic pain treated the third indication for duloxetine be. Duloxetine was in August 2004 in August 2004 under the brand name Yentreve? and AriClaim?* For the treatment of women with moderate to severe stress urinary incontinence and was approved in December 2004 under the brand name Cymbalta? and Xeristar?* For the treatment of depression.